3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
11
Prostatic Neoplasms
9
Carcinoma, Renal Cell
9
Melanoma
4
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Colorectal Neoplasms
2
Urothelial Cancer
1
Sarcoma
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Muscle-invasive Bladder Cancer
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Invasive Bladder Cancer
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
13
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
dodecyl maltoside
5
Radiotherapy
5
Cystoscopy
5
apaziquone
4
ALT-803
4
tislelizumab
3
5-aminolevulinic acid hexyl ester
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
Administration, Intravesical
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
tremelimumab
×
Genitourinary
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled